Health surveys; Muscle function; Physical functional performance; Cross-Cultural Comparison; Cross-Sectional Studies; Humans; Language; Psychometrics; Reproducibility of Results; Surveys and Questionnaires; Translations; Quality of Life; Sarcopenia/diagnosis; Sarcopenia; Rheumatology; Orthopedics and Sports Medicine
Abstract :
[en] [en] BACKGROUND: In 2015, a specific health-related quality of life questionnaire for sarcopenia, SarQoL®, was developed and validated in French. Since then, SarQoL® has been adapted and validated in different languages. We prepared a translation, cultural adaptation and validation of the psychometric properties of the SarQoL® into Spanish.
METHODS: A cross-sectional study with 86 participants. The translation and adaptation followed international guidelines with two direct translations, a synthesized version of the direct translations, two reverse translations, consensus by an expert committee of a pre-final version, pre-test by end users and final version. The discriminative power (logistic regression analyses), construct validity (Pearson and Spearman´s correlation), internal consistency (Cronbach´s alpha coefficient), test-retest reliability (intraclass correlation coefficient) and ceiling and floor effects were analyzed.
RESULTS: The Spanish version showed good construct validity (high correlation with comparable domains of the SF-36), high internal consistency (Cronbach's alpha coefficient: 0.84) and excellent test-retest reliability (ICC: 0.967, 95%, CI 0.917 - 0.989). However, it had no discriminative power between sarcopenic and non-sarcopenic participants defined with the EWGSOP and FNIH diagnostic criteria of sarcopenia. It did show discriminative power between patients with decreased vs normal muscle strength (54.9 vs. 62.6, p 0.009) and low vs. normal physical performance (57.3 vs. 70.2; p 0.005). No ceiling or floor effect was found.
CONCLUSIONS: The Spanish version of SarQoL® has similar psychometric properties to those of the original version of the instrument. It did not discriminate between sarcopenic and non-sarcopenic patients diagnosed according to the EWGSOP or FNIH criteria, but it did with those with low muscle strength and low physical performance.
Disciplines :
Public health, health care sciences & services
Author, co-author :
Montero-Errasquín, Beatriz ; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain. beatriz.montero@salud.madrid.org
Vaquero-Pinto, Nieves; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain
Sánchez-Cadenas, Vicente; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain
Geerinck, Anton ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Sánchez-García, Elisabet; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain
Mateos-Nozal, Jesús; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain
Ribera-Casado, José Manuel; Facultad de Medicina, Universidad Complutense de Madrid, Pl. de Ramón y Cajal, s/n, 28040, Madrid, Spain
Cruz-Jentoft, Alfonso J; Servicio de Geriatría, Hospital Universitario Ramón Y Cajal, IRYCIS Madrid, Ctra Colmenar km 9,100, 28034, Madrid, Spain
Language :
English
Title :
Spanish translation, cultural adaptation and validation of the SarQoL®: a specific health-related quality of life questionnaire for sarcopenia.
We would like to thank Dr. Charlotte Beaudart and Dr. Olivier Bruyère and the authors of the original Belgian questionnaire for their help. All the process and design of this study were done with their collaboration and authorization.
Sanchez-Rodriguez D, Marco E, Cruz-Jentoft AJ. Defining sarcopenia: some caveats and challenges. Curr Opin Clin Nutr Metab Care. 2020;23(2):127–32. 10.1097/MCO.0000000000000621. DOI: 10.1097/MCO.0000000000000621
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16–31. 10.1093/ageing/afy169. DOI: 10.1093/ageing/afy169
Goates S, Du K, Arensberg MB, Gaillard T, Guralnik J, Pereira SL. Economic impact of hospitalizations in US adults with Sarcopenia. J Frailty Aging 2019;8(2):93–9. 10.14283/jfa.2019.10. DOI: 10.14283/jfa.2019.10
Beaudart C, Rizzoli R, Bruyère O, Reginster J-Y, Biver E. Sarcopenia: burden and challenges for public health. Arch Public Health. 2014;72(1):45. 10.1186/2049-3258-72-45. DOI: 10.1186/2049-3258-72-45
Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Health Outcomes of Sarcopenia: A Systematic Review and Meta-Analysis Wright JM, ed. PLoS ONe. 2017;12(1):e0169548. 10.1371/journal.pone.0169548. DOI: 10.1371/journal.pone.0169548
Costanzo L, De Vincentis A, Di Iorio A, et al. Impact of Low Muscle Mass and Low Muscle Strength According to EWGSOP2 and EWGSOP1 in Community-Dwelling Older People. Newman A, ed. J Gerontol Ser A. 2020;75(7):1324–30. 10.1093/gerona/glaa063. DOI: 10.1093/gerona/glaa063
Xu J, Wan CS, Ktoris K, Reijnierse EM, Maier AB. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontol. 2021;27:1–16. 10.1159/0005170999. DOI: 10.1159/0005170999
Tsekoura M, Kastrinis A, Katsoulaki M, Billis E, Gliatis J. Sarcopenia and Its Impact on Quality of Life. Adv Exp Med Biol. 2017;987:213–8. 10.1007/978-3-319-57379-3_19. DOI: 10.1007/978-3-319-57379-3_19
Rizzoli R, Reginster J-Y, Arnal J-F, et al. Quality of Life in Sarcopenia and Frailty. Calcif Tissue Int. 2013;93(2):101–20. 10.1007/s00223-013-9758-y. DOI: 10.1007/s00223-013-9758-y
Badia X. La evaluación de la calidad de vida en el contexto del ensayo clínico. Med Clin. 1998;110(14):550–6. PMID: 9646272.
Guyatt GH. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ.1989;140(12):1441-8. PMID: 2655856.
Chew J, Yeo A. Yew S, et al. Muscle strength definitions matter: prevalence of sarcopenia and predictive validity for adverse oytcomes using the Euroepan Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. J Nutr Health Aging. 2020;24(6):614–8. 10.1007/s12603-020-1371y. DOI: 10.1007/s12603-020-1371y
Umegaki H, Bonfiglio V, Komiya H, et al. Association between sarcopenia and quality of life in patients with early dementia and mild cognitive impairment. J Alzheimer Dis. 2020;76(1):435–42. 10.3233/JAD-200169. DOI: 10.3233/JAD-200169
Beaudart C, Locquet M, Reginster J-Y, Delandsheere L, Petermans J, Bruyère O. Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions. Aging Clin Exp Res. 2018;30(4):307–13. 10.1007/s40520-017-0866-9. DOI: 10.1007/s40520-017-0866-9
Beaudart C, Reginster JY, Petermans J, Bruyère O. Quality of life of sarcopenic patients: contribution of the SarcoPhAge study. Geriatr Psychol Neuropsychiatr Vieil. 2015;13:391–5. 10.1684/pnv.2015.0571. DOI: 10.1684/pnv.2015.0571
Beaudart C, Biver E, Reginster J-Y, et al. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing. 2015;44(6):960–6. 10.1093/ageing/afv133. DOI: 10.1093/ageing/afv133
Beaudart C, Biver E, Reginster J-Y, et al. Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia: Validation of the SarQoL® questionnaire. J Cachexia Sarcopenia Muscle. 2017;8(2):238–44. 10.1002/jcsm.12149. DOI: 10.1002/jcsm.12149
Beaudart C, Edwards M, Moss C, et al. English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age Ageing. 2017;46(2):271–6. doi. 10.1093/ageing/afw192.
Gasparik AI, Mihai G, Beaudart C, et al. Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Arch Osteoporos. 2017;12(1):103. 10.1007/s11657-017-0397-1. DOI: 10.1007/s11657-017-0397-1
Geerinck A, Scheppers A, Beaudart C, et al. Translation and validation of the Dutch SarQoL®, a quality of life questionnaire specific to sarcopenia. J Musculoskelet Neuronal Interact. 2018;18(4):463–72. PMID: 30511950.
Konstantynowicz J, Abramowicz P, Glinkowski W, et al. Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. J Clin Med. 2018;7(10):323. doi. 10.3390/jcm7100323. DOI: 10.3390/jcm7100323
SafonovaYuA, Lesnyak OM, Baranova IA, et al. Russian translation and validation of SarQoL® – quality of life questionnaire for patients with sarcopenia. Rheumat Sci and Practice. 2019;57(1):38–45. doi. (In Russ).;): 10.14412/1995-4484-2019-38-45. DOI: 10.14412/1995-4484-2019-38-45
Alekna V, Kilaite J, Tamulaitiene M, et al. Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL®). Eur Geriatr Med. 2019;10(5):761–7. 10.1007/s41999-019-00208-x. DOI: 10.1007/s41999-019-00208-x
Tsekoura M, Billis E, Gliatis J, et al. Cross cultural adaptation of the Greek sarcopenia quality of life (SarQoL) questionnaire. Disabil Rehabil. 2020;42(7):1006–12. doi. 10.1080/09638288.2018.1514076. DOI: 10.1080/09638288.2018.1514076
Le X, Wei Y, Hao D, et al. Psychometric Properties of the Chinese Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia. Calcif Tissue Int. 2021;109(4):415–22. 10.1007/s00223-021-00859-8. DOI: 10.1007/s00223-021-00859-8
Erdogan T, Eris S, Avci S, et al. Sarcopenia quality-of-life questionnaire (SarQoL)®: translation, cross-cultural adaptation and validation in Turkish. Aging Clin Exp Res. 2021;33(11):2979–88. 10.1007/s40520-020-01780-0. DOI: 10.1007/s40520-020-01780-0
Fábrega-Cuadros R, Martinez-Amat A, Cruz-Díaz D, et al. Psychometric properties of the Spanish version of the sarcopenia and quality of life, a quality of life questionnaire specific for sarcopenia. Calcif Tissue Int. 2020;106(3):274–82. 10.1007/s00223-019-00635-9. DOI: 10.1007/s00223-019-00635-9
Landi F, Cesari M, Calvani R, et al. The “Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies” (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res. 2017;29(1):89–100. 10.1007/s40520-016-0715-2. DOI: 10.1007/s40520-016-0715-2
Guralnik JM, Simonsick EM, Ferucci L, Glynn RJ, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49(2):85–94. 10.1093/geronj/49.2.m85. DOI: 10.1093/geronj/49.2.m85
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. 10.1093/ageing/afq034. DOI: 10.1093/ageing/afq034
Roberts HC, Denison HJ, Martin HJ, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9. 10.1093/ageing/afr051. DOI: 10.1093/ageing/afr051
Studenski SA, Peters KW, Alley DE, et al. The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. J Gerontol Ser A. 2014;69(5):547–58. 10.1093/gerona/glu010. DOI: 10.1093/gerona/glu010
McLean RR, Shardell MD, Alley DE, et al. Criteria for Clinically Relevant Weakness and Low Lean Mass and Their Longitudinal Association With Incident Mobility Impairment and Mortality: The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project. J Gerontol Ser A. 2014;69(5):576–83. 10.1093/gerona/glu012. DOI: 10.1093/gerona/glu012
Ramada-Rodilla JM, Serra-Pujadas C, Delclós-Clanchet GL. Adaptación cultural y validación de cuestionarios de salud: revisión y recomendaciones metodológicas. Salud Pública México. 2013;55(1):57–66. 10.1590/S0036-36342013000100009. DOI: 10.1590/S0036-36342013000100009
Carvajal A, Centeno C, Watson R, Martinez M, Rubiales AS. How is an instrument for measuring health to be validated? Sist Sanit Navar. 2011;34(1):63–72. 10.4321/s1137-66272011000100007. DOI: 10.4321/s1137-66272011000100007
Guillemin F. Cross-cultural adaptation and validation of health status measures. Scand J Rheumatol. 1995;24(2):61–3. 10.3109/03009749509099285. DOI: 10.3109/03009749509099285
Alexandre NMC, Guirardello Ede B. Cultural adaptation of instruments utilized in occupational health. Rev Panam Salud Publica. 2002;11:109–11. 10.1590/s1020-49892002000200007. DOI: 10.1590/s1020-49892002000200007
Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the Process of Cross-Cultural Adaptation of Self-Report Measures. Spine. 2000;25(24):3186–91. 10.1097/00007632-200012150-00014. DOI: 10.1097/00007632-200012150-00014
Herdman M, Fox-Rushby J, Badia XA. A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach. Qual Life Res. 1998;7:323–35. 10.1023/a:1024985930536. DOI: 10.1023/a:1024985930536
Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol. 2015;68(4):435–41. 10.1016/j.jclinepi.2014.11.021. DOI: 10.1016/j.jclinepi.2014.11.021
Sperber AD. Translation and validation of study instruments for cross-cultural research. Gastroenterology. 2004;126:124–8. 10.1053/j.gastro.2003.10.016. DOI: 10.1053/j.gastro.2003.10.016
Ware JE Jr, Gandec B, Keller S. Evaluating instruments used cross-nationally: Methods from the IQOLA Project. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. 2a ed. Lippincort-Raven Publishers; 1996:681–692.
Terwee CB, Bot SDM, de Boer MR, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34–42. 10.1016/j.jclinepi.2006.03.012. DOI: 10.1016/j.jclinepi.2006.03.012
Alonso J, Prieto JM, Antó JM. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin. 1995;104:771–6. PMID: 7783470.
Kind P, Brooks R, Rabin R. 2005. EQ-5D Concepts and Methods: A Developmental History. Springer International Publishing; 10.1016/j.socscimed.2019.112560.
Badia X, Roset M, Montserrrat S, Herdman M, Segura A. La versión española del EuroQol: descripción y aplicaciones. Med Clin. 1999;112:79–85. PMID: 10618804.
Bahat G, Kilic C, Altinkaynak M, Akif Karan M. Comparison of standard versus population-specific handgrip strength cut-off points in the detection of probable sarcopenia after launch of EWGSOP2. Aging Male. 2020;23(5):1564–9. 10.1080/13685538.2020.1870038. DOI: 10.1080/13685538.2020.1870038
Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311(23):2387–96. 10.1001/jama.2014.5616. DOI: 10.1001/jama.2014.5616
Marques LP, Confortin SC, Ono LM, Barbosa AR, d’Orsi E. Quality of life associated with handgrip strength and sarcopenia: EpiFloripa Aging Study. Arch Gerontol Geriatr. 2019;81:234–9. 10.1016/j.archger.2018.12.015. DOI: 10.1016/j.archger.2018.12.015
Geerinck A, Beaudart C, Reginster JY, et al. Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL. Qual Life Res. 2021;30(8):2349–62. 10.1007/s11136-021-02823-3. DOI: 10.1007/s11136-021-02823-3
